Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial
08. Oktober 2024 08:30 ET
|
OncoCyte Corporation
Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO...
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
30. Mai 2024 16:47 ET
|
OncoCyte Corporation
Late-breaking presentation of data at American Transplant Congress on Monday, June 3Data show potential to monitor for therapeutic efficacy and recurrencePotential repeat testing opportunities with...